7-methyloctane-3,5-dione | 21890-66-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 7-methyloctane-3,5-dione
• 英文别名: 7-methyl-octane-3,5-dione；7-Methyl-octan-3,5-dion
• CAS: 21890-66-4
• 化学式: C₉H₁₆O₂
• mdl: MFCD08700476
• 分子量: 156.225
• InChiKey: PKAVSIHPPVFDHU-UHFFFAOYSA-N

物化性质

• 沸点：
  92-93 °C(Press: 20 Torr)
• 密度：
  0.909±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.777
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7-methyloctane-3,5-dione 生成 7-methyl-octane-3,5-dione 4,5-enol tautomer
  参考文献：
  名称：

  Effect of Substituents on the Keto-Enol Equilibrium of Alkyl-substituted β-Diketones

  摘要：

  DOI：

  10.1246/bcsj.46.632
• 作为产物：
  描述：

  7-methyl-octane-3,5-dione 4,5-enol tautomer 生成 7-methyloctane-3,5-dione
  参考文献：
  名称：

  Effect of Substituents on the Keto-Enol Equilibrium of Alkyl-substituted β-Diketones

  摘要：

  DOI：

  10.1246/bcsj.46.632

文献信息

• Inhibitors of Protein Tyrosine Kinase Activity
  申请人：Raeppel Stëphane

  公开号：US20110257100A1

  公开（公告）日：2011-10-20

  This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions.

  本发明涉及抑制蛋白酪氨酸激酶活性的化合物。特别是，本发明涉及抑制生长因子受体的蛋白酪氨酸激酶活性的化合物，从而抑制受体信号传导，例如，抑制VEGF受体信号传导。本发明还提供了用于治疗细胞增殖性疾病和条件以及眼科疾病、障碍和条件的化合物、组合物和方法。
• Preparation of a microsized cerium chloride-based catalyst and its application in the Michael addition of β-diketones to vinyl ketones
  作者：Alexander O. Terent'ev、Vera A. Vil'、Ivan A. Yaremenko、Oleg V. Bityukov、Dmitri O. Levitsky、Vladimir V. Chernyshev、Gennady I. Nikishin、Fabrice Fleury

  DOI：10.1039/c3nj01454a

  日期：——

  evaporation of its alcoholic solutions. The way of the preparation of the cerium chloride-based catalyst plays a decisive role in its catalytic activity. This catalyst is efficient in the Michael addition of β-diketones to vinyl ketones giving β,δ-triketones.

  开发了一种不需要特殊设备的简便方法，该方法可通过对CeCl 3 ·7H 2 O进行热处理或将其乙醇溶液蒸发来制备微细氯化铈。氯化铈基催化剂的制备方式对其催化活性起决定性作用。该催化剂在将β-二酮迈克尔加成到乙烯基酮中产生β，δ-三酮方面是有效的。
• Method For Producing Pyrimidinylpyrazole Compounds
  申请人：Fukunishi Hirotada

  公开号：US20120283441A1

  公开（公告）日：2012-11-08

  The present invention provides a method for producing a pyrimidinylpyrazole compound (1), wherein aminoguanidine (2) or its salt is reacted with a β-diketone compound (3) to produce the pyrimidinylpyrazole compound: wherein R 1 and R 3 are each independently an alkyl group having 1 to 4 carbon atoms, and R 2 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms. The method is excellent in the environmental compatibility and economic efficiency.

  本发明提供了一种生产嘧啶基吡唑化合物（1）的方法，其中氨基胍（2）或其盐与β-二酮化合物（3）反应，以产生嘧啶基吡唑化合物：其中R1和R3分别独立地是具有1至4个碳原子的烷基基团，而R2是氢原子或具有1至4个碳原子的烷基基团。该方法在环境兼容性和经济效益方面表现出色。
• [EN] CRYSTALLINE FORM OF PRAVASTATINE AND PROCESS FOR THE PREPARATION THEREOF<br/>[FR] FORME CRISTALLINE DE LA PRAVASTATINE ET SON PROCÉDÉ DE PRÉPARATION
  申请人：DSM SINOCHEM PHARM NL BV

  公开号：WO2012085191A1

  公开（公告）日：2012-06-28

  The present invention relates to a novel form of pravastatin, notably pravastatin sodium, and a method for the preparation of a novel form of pravastatin.

  本发明涉及一种新型普伐他汀的形式，特别是普伐他汀钠，并提供了一种制备新型普伐他汀形式的方法。
• [EN] PREPARATION PROCESS OF THE SODIUM SALT OF ESOMEPRAZOLE<br/>[FR] PROCÉDÉ DE PRÉPARATION DU SEL DE SODIUM DE L'ÉSOMÉPRAZOLE
  申请人：ESTEVE QUIMICA SA

  公开号：WO2011098553A1

  公开（公告）日：2011-08-18

  Preparation process of the sodium salt of a 2-(2-pyridylmethylsulfinyl)- benzimidazole derivative compound It comprises a preparation process of esomeprazole sodium substantially free of sulfone impurity comprising the steps of: a) combining either esomeprazole with a (C3-C8)-ketone or a mixture thereof, a sodium alkoxide, and a (C1-C5)-alcohol, or esomeprazole sodium with a (C3-C8)-ketone or a mixture thereof and a (C1-C5)-alcohol; and b) recovering the esomeprazole sodium formed from the reaction media by filtration.

  一种2-(2-吡啶甲基磺酰基)-苯并咪唑衍生物化合物的钠盐制备过程，包括制备基本无磺酰基杂质的埃索美拉唑钠的制备过程，包括以下步骤：a) 将埃索美拉唑与(C3-C8)酮或其混合物、钠烷基和(C1-C5)醇之一或其混合物，或将埃索美拉唑钠与(C3-C8)酮或其混合物和(C1-C5)醇之一或其混合物混合；b) 通过过滤从反应介质中回收形成的埃索美拉唑钠。